1. Home
  2. Live Updates
  3. Genitourinary oncology

Live Breaking News & Updates on Genitourinary Oncology

Stay updated with breaking news from Genitourinary oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Post-Surgery Immunotherapy Boosts Kidney Cancer Survival Rates

Post-Surgery Immunotherapy Boosts Kidney Cancer Survival Rates
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United States , Dana Farber Cancer Institute , Toni Choueiri , Dana Farber Brigham Cancer Center , Lank Center , Cancer Center , Blood Disorders Center , Harvard Medical School , American Society Of Clinical Oncology , Merck Co , Merck Sharp Dohme , Dana Farber Cancer , Genitourinary Oncology , American Society , Clinical Oncology , Genitourinary Cancer Symposium , Merck Sharp , Farber Cancer Institute , Comprehensive Cancer Center , Harvard Medical , Boston Children , Blood Disorders , World Report Best Cancer Hospital ,

Immunotherapy post-surgery found to improve overall survival for kidney cancer

Credit: Pixabay/CC0 Public Domain For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survi . ....

United States , Toni Choueiri , American Society Of Clinical Oncology , Dana Farber Cancer Institute , Lank Center , Dana Farber Cancer , Genitourinary Oncology , American Society , Clinical Oncology , Genitourinary Cancer Symposium ,

Frontline Pembrolizumab Plus Cabozantinib Elicits Responses in Cisplatin-Ineligible Urothelial Carcinoma

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma. ....

United States , Rohitk Jain , Genitourinary Oncology , Moffitt Cancer Center , Pembrolizumab Plus Cabozantinib , First Line Treatment Of Patients With Cisplatin Ineligible Urothelial Carcinoma , 2024 Asco Gu Symposium ,

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Region

RAHWAY, N.J. (BUSINESS WIRE) Jan 27, 2024 ....

United States , Michael Mcardle , Peter Dannenbaum , Damini Chokshi , Nancy Kohlberg , Tonik Choueiri , Julie Cunningham , Akeso Inc , Dana Farber Cancer Institute , Statement Of Merck Co Inc , European Union , Asco Gu Press Program , Merck Co Inc , Merck Research Laboratories , Exchange Commission , Lank Center , Harvard Medical School , American Society Of Clinical Oncology , Clinical Oncology , Cancers Symposium , Genitourinary Oncology , Harvard Medical , Marjorie Green , Merck Research , Positive Score , Selected Important Safety ,

Keytruda Plus Cabometyx Produces Responses in Cisplatin-Ineligible Bladder Cancer

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer. ....

United States , Rohitk Jain , Genitourinary Oncology , Moffitt Cancer Center , Bladder Cancer ,